Actively Recruiting

Phase 1
Age: 18Years +
All Genders
NCT04677413

Ultra-fractionated Radiotherapy for Rectal Cancer

Led by University of Texas Southwestern Medical Center · Updated on 2026-04-27

27

Participants Needed

1

Research Sites

312 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The rationale of this clinical trial is to assess the feasibility of selective non-operative management for locally advanced rectal cancer using dose-escalated ultra-fractionated short course radiation therapy interdigitated with chemotherapy. We believe delivering short course radiotherapy over a prolonged interval, at escalated doses and with concurrent chemotherapy may be feasible and allow for improved clinical response.

CONDITIONS

Official Title

Ultra-fractionated Radiotherapy for Rectal Cancer

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • At least 18 years of age
  • Able and willing to provide written informed consent
  • Pathologic diagnosis of rectal adenocarcinoma
  • T3-4 and/or N+ disease according to AJCC 8th edition
  • No prior treatment for rectal adenocarcinoma
  • Eastern Cooperative Group (ECOG) performance status of 0-2
  • Laboratory values within acceptable limits for organ and marrow function within 30 days prior, including:
    • WBC  3,000/mL
    • ANC WBC  1,000/mL
    • Platelets  75,000/mL
    • Total bilirubin  1.5 times upper limit of normal
    • AST/ALT  2.5 times upper limit of normal
    • Creatinine at or below upper limit of normal, or creatinine clearance above 50 mL/min/1.73 m2 if above institutional normal
  • Men and women of child-bearing potential must agree to use effective contraception from first dose through 90 days after last dose
  • Women of child-bearing potential defined as those who have not had hysterectomy or bilateral oophorectomy, or have had menses in past 12 months
Not Eligible

You will not qualify if you...

  • Presence of distant nodal disease including retroperitoneal or inguinal nodes or any metastatic disease by CT
  • Prior radiation therapy to the pelvis
  • Uncontrolled comorbid illnesses such as congestive heart failure, unstable angina, cardiac arrhythmia, or psychiatric illness limiting study compliance
  • Psychiatric illness or social situations limiting ability to consent or comply with study
  • Pregnancy or nursing due to risk of congenital abnormalities and potential harm to infants

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

UT Southwestern Medical Center

Dallas, Texas, United States, 75390-8849

Actively Recruiting

Loading map...

Research Team

B

Busayo Adefalujo

CONTACT

S

Sarah Neufeld

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NA

Model

SINGLE_GROUP

Primary Purpose

TREATMENT

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here